Literature DB >> 27039261

A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution.

Talia M Muram1, John H Sloan2, Jana S Chain2, Wendy J Komocsar2, Bruce I Meiklejohn2, Andrew Blauvelt3, Kim Papp4, Michael P Heffernan2, Yue-Wei Qian2, Robert J Konrad2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27039261     DOI： 10.1016/j.jid.2016.01.040

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  5 in total

Review 1.  Immunogenicity of biologic agents in rheumatology.

Authors:  Vibeke Strand; Joao Goncalves; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2020-12-14       Impact factor: 20.543

Review 2.  Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients.

Authors:  Romy Mosch; Henk-Jan Guchelaar
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

3.  Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Authors:  A Blauvelt; K A Papp; H Sofen; M Augustin; G Yosipovitch; N Katoh; U Mrowietz; M Ohtsuki; Y Poulin; D Shrom; R Burge; K See; L Mallbris; K B Gordon
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03-31       Impact factor: 6.166

4.  Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

Authors:  A B Kimball; T Kerbusch; F van Aarle; P Kulkarni; Q Li; A Blauvelt; K A Papp; K Reich; D Montgomery
Journal:  Br J Dermatol       Date:  2019-07-04       Impact factor: 9.302

5.  Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Authors:  Mark C Genovese; Eduardo Mysler; Tetsuya Tomita; Kim A Papp; Carlo Salvarani; Sergio Schwartzman; Gaia Gallo; Himanshu Patel; Jeffrey R Lisse; Andris Kronbergs; Soyi Liu Leage; David H Adams; Wen Xu; Helena Marzo-Ortega; Mark G Lebwohl
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.